HK Stock Market Move | The Pacific Shipping (02343) opened nearly 5% higher after its results, with mid-term net profit attributable to shareholders increasing by 310.35% year-on-year.
Pacific Shipping (02343) opened nearly 5% higher after earnings, and as of the time of publication, it has risen by 4.79%, trading at HKD 3.5, with a transaction volume of HKD 3.479 million.
The Pacific Shipping (02343) opened nearly 5% higher post-results, and as of the time of publication, was up 4.79%, at HKD 3.50, with a transaction volume of HKD 3.479 million.
On August 6, The Pacific Shipping announced its interim results for the six months ending June 30, 2026, reporting a revenue of USD 1.105 billion, an increase of 8.52% year-on-year; a profit attributable to shareholders of USD 105 million, an increase of 310.35% year-on-year; and basic earnings per share of 2.06 cents. A mid-term dividend of 15.5 HK cents per share is proposed.
The announcement stated that in the first half of 2026, the groups core business contributed USD 124 million (excluding management expenses), growing 144% compared to the first half of 2025. The daily average earnings for the groups small handy and ultra-handy bulk carriers under time charter contracts were USD 14,200 and USD 16,600, respectively, exceeding the market indices by USD 1,950 and USD 2,370. This outstanding performance highlights the value of the groups integrated platform and continues its long-standing record of outperforming freight market benchmarks.
Related Articles
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
RECOMMEND
